Clinical Trial Update: A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002 [Phase 3]

View source ↗

Summary

Phase III trial evaluating DWP-450 for safety and efficacy in treating glabellar lines has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines

Drugs mentioned

• DWP-450 (botulinum toxin type A)

Snippet

Sponsor: Evolus, Inc. | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED | Results posted: 2019-02-27